Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402)

Anticancer Research

Volumn 34, Issue 2, 2014, Pages 851-858

  Sugimoto, Naotoshi ^a,h   Fujitani, Kazumasa ^b,h   Imamura, Hiroshi ^c,h   Uedo, Noriya ^a,h   Iijima, Shohei ^d,h   Imano, Motohiro ^e,h   Shimokawa, Toshio ^f,h   Kurokawa, Yukinori ^b,h   Furukawa, Hiroshi ^c,h   Goto, Masahiro ^g,h  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c SAKAI MUNICIPAL HOSPITAL   (Japan)

^d Mino City Hospital   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF YAMANASHI   (Japan)

^g OSAKA MEDICAL COLLEGE   (Japan)

^h Osaka Gastrointestinal Cancer Chemotherapy Study Group   (Japan)

Author keywords

Gastric cancer; Irinotecan; Paclitaxel; Phase ii study; S 1

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; PACLITAXEL; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG COMBINATION; MIDDLE AGED; S-1; STOMACH CANCER; STOMACH TUMOR;

GASTRIC CANCER; IRINOTECAN; PACLITAXEL; PHASE II STUDY; S-1;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PACLITAXEL; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; TEGAFUR;

EID: 84897105271     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Foundation for Promotion of Cancer Research. Cancer Statistics in Japan 2011.Available from URL http://ganjoho.jp/professional/statistics/backnumber/2013-jp.html Accessed December 30, 2013.
2. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B and Wils JA: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18: 2648-2657, 2000.
3. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I and Falcon S: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28: 1547-1553, 2010.
4. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M and Hickish T: Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial. Br J Cancer 80: 269-272,1999.
5. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, and Van Cutem E: Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J ClinOncol 25: 3205-3209, 2007.
6. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36-46, 2008.
7. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H and Yoshida S: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J ClinOncol 21: 54-59, 2003.
8. Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T, Okabe H, Fujioka A, Nakano K, Ohshimo H, Takeda S and Shirasaka T: Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 13: 693-698, 1998.
9. Koizumi W, Kurihara M, Nakano S and Hasegawa K: Phase II study of S-1, A novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58: 191-197, 2000.
10. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998.
11. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, and Ohtsu A: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase III study. Lancet Oncol 10: 1063-1069, 2009.
12. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, and Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 9: 215-221, 2008.
13. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, Yoshino M, Taguchi T and Ogawa N: Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer: Gan To Kagaku Ryoho 21: 1033-1038, 1994 (in Japasese).
14. Uedo N, Narahara H, Ishihara R, Takiuchi H, Goto M, Fujitani K, Hirao M, Tsujinaka T, Imano M, Furukawa H, Tsukuma H and Taguchi T: Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002). Oncology 73: 65-71, 2007.
15. Arai T, Hamaguchi T, Shirao K, Shimada Y, Yamada Y, Muro K, Ura T and Goto A: Weekly paclitaxel (PTX) in patients with heavily treated advanced gastric cancer (AGC). Jpn J Cancer Clin 49: 621-625, 2003.
16. Narahara H, Fujitani K, Takiuchi H, Sugimoto N, Inoue K, Uedo N, Tsukuma H, Tsujinaka T, Furukawa H and Taguchi T: Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology 74: 37-41, 2008.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Chiristian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
18. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0. Aug 9, 2006.
19. Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C and Sakata Y: Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 14: 72-80, 2011. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf.
20. Fujii M, Kim YH, Satoh T, Hosaka H, Kim T, Tsuji A, Inokuchi M, Takagane T, Oh SC, Tanabe K, Okuno T, Chin K, Ura T, Lee JI, Kakudo Y, Yamaguchi K, Iijima S, Takeuchi M, Kim H and Nakajima T: Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): The START trial update. J Clin Oncol 29: (suppl 4; abstr 4016), 2011.
21. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J and Kang YK: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase III, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
22. Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmer P, Scherer SJ and Shah MA: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the avagast randomized phase III trial. J ClinOncol 30: 2119-2127, 2012.
23. Koizumi W, Takiuchi H, Yamada Y, Boku N, Fuse N, Muro K, Komatsu Y and Tsuburaya A: Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol 21: 1001-1005,2010.
24. Higuchi K, Koizumi W, Yamada Y, Nishikawa K, Goto M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Negoro Y, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Koizumi W, Hamada C and Hyodo I: Randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin for first-line treatment of advanced gastric cancer. J ClinOncol 30: (suppl 34; abstr 60), 2013.
25. Sugimoto N, Narahara H, Sakai D, Yamamoto S, Fumoto S, Yagi T, Imamura F, Iishi H and Tatsuta M: The effectiveness of S-1-based sequential chemotherapy as second-line treatment for advanced/recurrent gastric cancer. Gan To Kagaku Ryoho 36: 417-424, 2009 (in Japasese).